ID   SUSM-1
AC   CVCL_4903
SY   SUSM1
DR   CLO; CLO_0050043
DR   BioSample; SAMN03472342
DR   IARC_TP53; 5360
DR   RCB; RCB0174
DR   Wikidata; Q54970920
RX   CelloPub=CLPUB00712;
RX   DOI=10.11418/jtca1981.12.4_313;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=3140712;
RX   PubMed=3413074;
RX   PubMed=7705936;
RX   PubMed=8105370;
RX   PubMed=8148305;
RX   PubMed=8557247;
RX   PubMed=8744932;
RX   PubMed=8790940;
RX   PubMed=9175740;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=19935656;
CC   Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Heterozygous (PubMed=8790940).
CC   Transformant: ChEBI; CHEBI:16907; 4-nitroquinoline N-oxide (4NQO).
CC   Derived from site: In situ; Fetal liver; UBERON=UBERON_0002107.
CC   Cell type: Fibroblast; CL=CL_0000057.
ST   Source(s): RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 12
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   TH01: 8
ST   TPOX: 8,11
ST   vWA: 16,18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M811 ! HSF-412
SX   Male
AG   Fetus
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 21
//
RX   CelloPub=CLPUB00712;
RA   Henson J.D.;
RT   "The role of alternative lengthening of telomeres in human cancer.";
RL   Thesis PhD (2006), University of Sydney, Australia.
//
RX   DOI=10.11418/jtca1981.12.4_313;
RA   Namba M., Bai L., Kano Y., Sugihara S., Miyazaki M.;
RT   "Multistep malignant transformation of human cells: immortalization of
RT   human fibroblasts by treatment with 60Co gamma rays and 4-nitroquinoline
RT   1-oxide, and their malignant transformation with the ras oncogene.";
RL   Tissue Cult. Res. Commun. 12:313-318(1993).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=3140712;
RA   Namba M., Nishitani K., Fukushima F., Kimoto T.;
RT   "Multistep carcinogenesis of normal human fibroblasts. Human
RT   fibroblasts immortalized by repeated treatment with Co-60 gamma rays
RT   were transformed into tumorigenic cells with Ha-ras oncogenes.";
RL   Anticancer Res. 8:947-958(1988).
//
RX   PubMed=3413074; DOI=10.1073/pnas.85.16.6042;
RA   Pereira-Smith O.M., Smith J.R.;
RT   "Genetic analysis of indefinite division in human cells:
RT   identification of four complementation groups.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
//
RX   PubMed=7705936; DOI=10.1002/ijc.2910610113;
RA   Kawashima K., Mihara K., Usuki H., Shimizu N., Namba M.;
RT   "Transfected mutant p53 gene increases X-ray-induced cell killing and
RT   mutation in human fibroblasts immortalized with 4-nitroquinoline
RT   1-oxide but does not induce neoplastic transformation of the cells.";
RL   Int. J. Cancer 61:76-79(1995).
//
RX   PubMed=8105370; DOI=10.1128/mcb.13.10.6036-6043.1993;
RA   Ogata T., Ayusawa D., Namba M., Takahashi E., Oshimura M., Oishi M.;
RT   "Chromosome 7 suppresses indefinite division of nontumorigenic
RT   immortalized human fibroblast cell lines KMST-6 and SUSM-1.";
RL   Mol. Cell. Biol. 13:6036-6043(1993).
//
RX   PubMed=8148305;
RA   Namba M., Iijima M., Kondo T., Jahan I., Mihara K.;
RT   "Immortalization of normal human cells is a multistep process and a
RT   rate limiting step of neoplastic transformation of the cells.";
RL   Hum. Cell 6:253-259(1993).
//
RX   PubMed=8557247; DOI=10.1007/BF00218823;
RA   Sugihara S., Mihara K., Marunouchi T., Inoue H., Namba M.;
RT   "Telomere elongation observed in immortalized human fibroblasts by
RT   treatment with 60Co gamma rays or 4-nitroquinoline 1-oxide.";
RL   Hum. Genet. 97:1-6(1996).
//
RX   PubMed=8744932; DOI=10.18926/AMO/30489;
RA   Iijima M., Kano Y., Nohno T., Namba M.;
RT   "Cloning of cDNA with possible transcription factor activity at the
RT   G1-S phase transition in human fibroblast cell lines.";
RL   Acta Med. Okayama 50:73-77(1996).
//
RX   PubMed=8790940; DOI=10.1247/csf.21.111;
RA   Mihara K., Iijima M., Kondo T., Namba M.;
RT   "Selective expression of mutated p53 in human cells immortalized with
RT   either 4-nitroquinoline 1-oxide or 60Co gamma rays.";
RL   Cell Struct. Funct. 21:111-116(1996).
//
RX   PubMed=9175740; DOI=10.1093/hmg/6.6.921;
RA   Bryan T.M., Marusic L., Bacchetti S., Namba M., Reddel R.R.;
RT   "The telomere lengthening mechanism in telomerase-negative immortal
RT   human cells does not involve the telomerase RNA subunit.";
RL   Hum. Mol. Genet. 6:921-926(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=19935656; DOI=10.1038/nbt.1587;
RA   Henson J.D., Cao Y., Huschtscha L.I., Chang A.C.-M., Au A.Y.M.,
RA   Pickett H.A., Reddel R.R.;
RT   "DNA C-circles are specific and quantifiable markers of
RT   alternative-lengthening-of-telomeres activity.";
RL   Nat. Biotechnol. 27:1181-1185(2009).
//